{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:48:54Z","timestamp":1762177734255,"version":"3.37.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The Shugan Lidan Decoction and Chaihu Shugan formula are traditional Chinese medicine formulas for treating liver diseases, with a history of over a 1000 years. By comprehensively improving 2 traditional Chinese medicinal formulas, Shugan Lidan Xiaoshi Granules (SLXG) has been developed for the treatment of nonalcoholic fatty liver disease (NAFLD) and other liver-related metabolic diseases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>First, the effective active ingredients and targets of SLXG were determined using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform database. The treatment targets for NAFLD were identified using the GeneCards, OMIM, and CTD databases, and the intersection of the decoction and disease targets was obtained. The intersection targets were then subjected to protein\u2013protein interaction network analysis, Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis, and gene ontology enrichment analysis. KEGG enrichment analysis revealed enrichment of the NAFLD pathway. Molecular docking was performed to validate the binding between the crucial targets enriched in this pathway and the corresponding active ingredients in SLXG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 219 disease intersection genes related to NAFLD were identified from the GeneCards, OMIM, and CTD databases, and 239 non-duplicated drug targets were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform database. A total of 24 intersection target genes were obtained from both drug- and disease-related databases, with 6 genes enriched in the KEGG NAFLD pathway. Molecular docking results showed that the 13 gene\u2013active ingredient bindings had a binding energy of less than \u22126.5.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The use of network pharmacology and molecular docking technology has revealed the mechanism of action of SLXG in NAFLD treatment, thus laying a theoretical foundation for the clinical application of SLXG in NAFLD therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040255","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:02:44Z","timestamp":1739217764000},"page":"e40255","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the mechanism of SLXG for treating nonalcoholic fatty liver disease based on network pharmacology and molecular docking"],"prefix":"10.1097","volume":"104","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Intervention Medicine and Microinvasive Oncology, The Second Hospital of Shandong University, Jinan, China"},{"name":"Institute of Interventional Oncology, Shandong University, Jinan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Intervention Medicine and Microinvasive Oncology, The Second Hospital of Shandong University, Jinan, China"},{"name":"Institute of Interventional Oncology, Shandong University, Jinan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zitong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Intervention Medicine and Microinvasive Oncology, The Second Hospital of Shandong University, Jinan, China"},{"name":"Institute of Interventional Oncology, Shandong University, Jinan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Intervention Medicine and Microinvasive Oncology, The Second Hospital of Shandong University, Jinan, China"},{"name":"Institute of Interventional Oncology, Shandong University, Jinan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wujie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Intervention Medicine and Microinvasive Oncology, The Second Hospital of Shandong University, Jinan, China"},{"name":"Institute of Interventional Oncology, Shandong University, Jinan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8117-4317","authenticated-orcid":false,"given":"Yuliang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Intervention Medicine and Microinvasive Oncology, The Second Hospital of Shandong University, Jinan, China"},{"name":"Institute of Interventional Oncology, Shandong University, Jinan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250210","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cld.2023.01.008","article-title":"Current treatment options, including diet, exercise, and medications: the impact on histology.","volume":"27","author":"Noureddin","year":"2023","journal-title":"Clin Liver Dis"},{"key":"R2-20250210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jare.2018.12.006","article-title":"Beneficial role of bioactive lipids in the pathobiology, prevention, and management of HBV, HCV and alcoholic hepatitis, NAFLD, and liver cirrhosis: a review.","volume":"17","author":"Das","year":"2019","journal-title":"J Adv Res"},{"key":"R3-20250210","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.metop.2021.100149","article-title":"Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD).","volume":"12","author":"Zarghamravanbakhsh","year":"2021","journal-title":"Metabol Open"},{"key":"R4-20250210","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/apt.14952","article-title":"Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view.","volume":"48","author":"Bessone","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R5-20250210","first-page":"359","article-title":"Recent knowledge on the pathogenesis of nonalcoholic fatty liver disease. Role of genetic factors.","volume":"101","author":"Miele","year":"2010","journal-title":"Recenti Prog Med"},{"key":"R6-20250210","first-page":"597","article-title":"Nonalcoholic fatty liver disease and weight loss.","volume":"40","author":"Ping","year":"2018","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"R7-20250210","doi-asserted-by":"crossref","first-page":"100117","DOI":"10.1016\/j.jhepr.2020.100117","article-title":"Imaging and immunometabolic phenotyping uncover changes in the hepatic immune response in the early phases of NAFLD.","volume":"2","author":"Diniz","year":"2020","journal-title":"JHEP Rep"},{"key":"R8-20250210","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1055\/s-0042-1757712","article-title":"NAFLD in cardiovascular diseases: a contributor or comorbidity?","volume":"42","author":"Chen","year":"2022","journal-title":"Semin Liver Dis"},{"key":"R9-20250210","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1017\/S1092852922001043","article-title":"The bidirectional association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia.","volume":"28","author":"Jawad","year":"2023","journal-title":"CNS Spectr"},{"key":"R10-20250210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13578-022-00836-0","article-title":"Novel insights into non-alcoholic fatty liver disease and dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular impairment, and inflammation.","volume":"12","author":"Cheon","year":"2022","journal-title":"Cell Biosci"},{"key":"R11-20250210","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12916-020-01713-8","article-title":"Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches.","volume":"18","author":"Soto-Angona","year":"2020","journal-title":"BMC Med"},{"key":"R12-20250210","first-page":"1659","article-title":"Exploration on an overview of history (from Chunqiu to Ming and Qing Dynasties) and species of Chinese exotic traditional medicine.","volume":"42","author":"Jia","year":"2017","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"R13-20250210","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12906-022-03697-9","article-title":"Salvia-Nelumbinis naturalis improves lipid metabolism of NAFLD by regulating the SIRT1\/AMPK signaling pathway.","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Complement Med Ther"},{"key":"R14-20250210","doi-asserted-by":"crossref","first-page":"1381712","DOI":"10.3389\/fphar.2024.1381712","article-title":"Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review.","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Pharmacol"},{"key":"R15-20250210","doi-asserted-by":"crossref","first-page":"9390786","DOI":"10.1155\/2018\/9390786","article-title":"Chaihu-Shugan-San decoction modulates intestinal microbe dysbiosis and alleviates chronic metabolic inflammation in NAFLD rats via the NLRP3 inflammasome pathway.","volume":"2018","author":"Liang","year":"2018","journal-title":"Evid Based Complement Alternat Med"},{"key":"R16-20250210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11655-016-2252-4","article-title":"Protective Effects of Chaihu Shugan San () on nonalcoholic fatty liver disease in rats with insulin resistance.","volume":"24","author":"Jiang","year":"2018","journal-title":"Chin J Integr Med"},{"key":"R17-20250210","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v11i2.3559","article-title":"Lead drug discover strategies from natural medicines based on network pharmacology.","volume":"11","author":"Ma","year":"2023","journal-title":"Med Res Arch"},{"key":"R18-20250210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10822-010-9352-6","article-title":"Ligand docking and binding site analysis with PyMOL and Autodock\/Vina.","volume":"24","author":"Seeliger","year":"2010","journal-title":"J Comput Aided Mol Des"},{"key":"R19-20250210","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018.","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"R20-20250210","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1289\/ehp.6028","article-title":"The Comparative Toxicogenomics Database (CTD).","volume":"111","author":"Mattingly","year":"2003","journal-title":"Environ Health Perspect"},{"key":"R21-20250210","doi-asserted-by":"crossref","first-page":"D789","DOI":"10.1093\/nar\/gku1205","article-title":"OMIM.org: Online Mendelian Inheritance in Man (OMIM(R)), an online catalog of human genes and genetic disorders.","volume":"43","author":"Amberger","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"R22-20250210","first-page":"213","article-title":"p38 MAPK signal pathway involved in anti-inflammatory effect of Chaihu-Shugan-San and Shen-ling-bai-zhu-San on hepatocyte in non-alcoholic steatohepatitis rats.","volume":"11","author":"Yang","year":"2014","journal-title":"Afr J Tradit Complement Altern Med"},{"key":"R23-20250210","doi-asserted-by":"crossref","first-page":"7726","DOI":"10.1021\/acs.jafc.9b02523","article-title":"Polyphenol-rich loquat fruit extract prevents fructose-induced nonalcoholic fatty liver disease by modulating glycometabolism, lipometabolism, oxidative stress, inflammation, intestinal barrier, and gut microbiota in mice.","volume":"67","author":"Li","year":"2019","journal-title":"J Agric Food Chem"},{"key":"R24-20250210","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.3390\/molecules28104042","article-title":"Lactiplantibacillus plantarum NKK20 alleviates high-fat-diet-induced nonalcoholic fatty liver disease in mice through regulating bile acid anabolism.","volume":"28","author":"Sun","year":"2023","journal-title":"Molecules"},{"key":"R25-20250210","doi-asserted-by":"crossref","first-page":"113997","DOI":"10.1016\/j.fct.2023.113997","article-title":"Tartary buckwheat root polysaccharides ameliorate non-alcoholic fatty liver disease via the IL6-SOCS3-SREBP1c pathway.","volume":"179","author":"Zhang","year":"2023","journal-title":"Food Chem Toxicol"},{"key":"R26-20250210","doi-asserted-by":"crossref","first-page":"101331","DOI":"10.1016\/j.molmet.2021.101331","article-title":"PAQR9 regulates hepatic ketogenesis and fatty acid oxidation during fasting by modulating protein stability of PPARalpha.","volume":"53","author":"Lin","year":"2021","journal-title":"Mol Metab"},{"key":"R27-20250210","doi-asserted-by":"crossref","first-page":"e0166048","DOI":"10.1371\/journal.pone.0166048","article-title":"Pro-inflammatory cytokines but not endotoxin-related parameters associate with disease severity in patients with NAFLD.","volume":"11","author":"du Plessis","year":"2016","journal-title":"PLoS One"},{"key":"R28-20250210","doi-asserted-by":"crossref","first-page":"22173","DOI":"10.3390\/ijms151222173","article-title":"Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease.","volume":"15","author":"Auguet","year":"2014","journal-title":"Int J Mol Sci"},{"key":"R29-20250210","doi-asserted-by":"crossref","first-page":"109761","DOI":"10.1016\/j.abb.2023.109761","article-title":"Identification of potential inhibitors against E.coli via novel approaches based on deep learning and quantum mechanics-based atomistic investigations.","volume":"747","author":"Aziz","year":"2023","journal-title":"Arch Biochem Biophys"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:02:51Z","timestamp":1739217771000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040255","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}